#RepeatedMildClosedHeadInjury triggers sustained #neuroimmune and complement activation—marked by #microglial recruitment and #CognitiveImpairment—while post-injury #ComplementInhibition significantly mitigates these pathological changes.

#CoverPage in #STTT: doi.org/10.1038/s413...

Pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor therapy indicated for TA-TMA.
More info: bit.ly/497VHeF
#YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA

#RepeatedMildClosedHeadInjury activates complement-driven neuroimmune responses, induces #microglial dysfunction and #neurodegenerative pathways, and post-injury #ComplementInhibition can reverse these effects,

#OpenAccess in #STTT: doi.org/10.1038/s413...

The Rational Use of Complement Inhibitors in Kidney Diseases The development of complement inhibitors represented one of the major breakthroughs in clinical nephrology in the last decade. Complement inhibition has dramatically transformed the outcome of one of the most severe kidney diseases, the atypical hemolytic uremic syndrome (aHUS), a prototypic complement-mediated disorder. The availability of complement inhibitors has also opened new promising perspectives for the management of several other kidney diseases in which complement activation is involved to a variable extent.

"The activation of the #complement system is not necessarily harmful in all settings, and hence #complementinhibition is not necessarily beneficial in all conditions."
#kireport

The Rational Use of Complement Inhibitors in Kidney Diseases

kireports.org/article/S2468-…

The Rational Use of Complement Inhibitors in Kidney Diseases The development of complement inhibitors represented one of the major breakthroughs in clinical nephrology in the last decade. Complement inhibition has dramatically transformed the outcome of one of the most severe kidney diseases, the atypical hemolytic uremic syndrome (aHUS), a prototypic complement-mediated disorder. The availability of complement inhibitors has also opened new promising perspectives for the management of several other kidney diseases in which complement activation is involved to a variable extent.

"The activation of the #complement system is not necessarily harmful in all settings, and hence #complementinhibition is not necessarily beneficial in all conditions."
#kireport

The Rational Use of Complement Inhibitors in Kidney Diseases

kireports.org/article/S2468-…